Other News To Note
Tuesday, September 25, 2012
Cannabis Science Inc., of Colorado Springs, Colo., said it started preclinical work in Europe for squamous/basal cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity using cannabinoids that have been demonstrated in recent studies to significant affect tumor necrosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.